Indivior Pharmaceuticals, Inc. Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Indivior Pharmaceuticals, Inc. shares issued, shares, share-based payment arrangement, after forfeiture for fiscal 2024 was 1.00M shares, a 50.00% decline from fiscal 2023.
- Indivior Pharmaceuticals, Inc. shares issued, shares, share-based payment arrangement, after forfeiture for fiscal 2023 was 2.00M shares, a 50.00% decline from fiscal 2022.
- Indivior Pharmaceuticals, Inc. shares issued, shares, share-based payment arrangement, after forfeiture for fiscal 2022 was 4.00M shares.
| Period end | Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture 3 month | Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture 12 month |
|---|---|---|
| 2024-12-31 | 1.00M shares 10-K · filed 2025-03-03 | |
| 2023-12-31 | 2.00M shares 10-K · filed 2025-03-03 | |
| 2022-12-31 | 4.00M shares 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |